{"title":"The protective effects of ulinastatin on liver function in patients with liver cancer after major hepatectomy","authors":"Yi-lei Deng, Zhiwei Liang, Shuai Du, Weibo Zhang, Wei Feng, Menghao Zhou, Longshuan Zhao","doi":"10.3760/CMA.J.CN113855-20190620-00339","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effects of ulinastatin on liver function in patients with liver cancer after major hepatectomy. \n \n \nMethods \nThe clinical data of 232 patients with major liver resection due to liver cancer were retrospectively analyzed. According to whether ulinastatin was applied after operation, patients were divided into treatment group (105 cases) and control group (127 cases). The postoperative inflammatory factors, liver function, postoperative complications and hospital stay were compared. \n \n \nResults \nThe levels of CRP、IL-6 and TBIL、ALT、AST were significantly lower than the control group 3 days after surgery (CRP: t=4.520, P=0.000; IL-6: t=17.982, P=0.000; TBIL: t=9.843, P=0.000; ALT: t=11.913, P=0.000; AST: t=4.520, P=0.000). The incidence of massive ascites in the treatment group (χ2=4.212, P=0.040) and the average postoperative hospital stay (t=9.994, P=0.000) were significantly lower than that in the control group. \n \n \nConclusion \nEarly application of ulinastatin effectively inhibits the inflammatory process, protects liver function, reduces the incidence of massive ascites, and shortens the postoperative hospital stay. \n \n \nKey words: \nHepatectomy; Inflammation; Liver function tests","PeriodicalId":66425,"journal":{"name":"中华普通外科杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华普通外科杂志","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN113855-20190620-00339","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To investigate the effects of ulinastatin on liver function in patients with liver cancer after major hepatectomy.
Methods
The clinical data of 232 patients with major liver resection due to liver cancer were retrospectively analyzed. According to whether ulinastatin was applied after operation, patients were divided into treatment group (105 cases) and control group (127 cases). The postoperative inflammatory factors, liver function, postoperative complications and hospital stay were compared.
Results
The levels of CRP、IL-6 and TBIL、ALT、AST were significantly lower than the control group 3 days after surgery (CRP: t=4.520, P=0.000; IL-6: t=17.982, P=0.000; TBIL: t=9.843, P=0.000; ALT: t=11.913, P=0.000; AST: t=4.520, P=0.000). The incidence of massive ascites in the treatment group (χ2=4.212, P=0.040) and the average postoperative hospital stay (t=9.994, P=0.000) were significantly lower than that in the control group.
Conclusion
Early application of ulinastatin effectively inhibits the inflammatory process, protects liver function, reduces the incidence of massive ascites, and shortens the postoperative hospital stay.
Key words:
Hepatectomy; Inflammation; Liver function tests